Colorectal Carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
These data suggest that inactivation of the DPC4 gene contributes to the genesis of colorectal carcinoma through allelic loss whereas mutation in the coding region of the DPC4 gene is infrequently detected in Croatian patients with A, B or C stages of colorectal cancers.
|
15063137 |
2004 |
Colorectal Carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
In the past two decades, multiple studies have revealed that SMAD4 loss on its own does not initiate tumor formation, but can promote tumor progression initiated by other genes, such as KRAS activation in pancreatic duct adenocarcinoma and APC inactivation in colorectal cancer.
|
29483830 |
2018 |
Colorectal Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
We used human CRC cell lines to investigate the ability of SMAD4 to regulate expression of CCL15, a human ortholog of mouse CCL9.
|
23891973 |
2013 |
Colorectal Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Statin therapy may only be effective in SMAD4-expressing CRCs and may have adverse effects in SMAD4-negative tumors.
|
17919499 |
2007 |
Colorectal Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Four hundred two patients (89.3%) had MMR-proficient tumors, and 32 patients (8%) had at least 1 gene mutation: 9 had mutations in high-penetrance CRC genes (5, APC; 1, APC/PMS2; 2, biallelic MUTYH; 1, SMAD4); 13 patients had mutations in high- or moderate-penetrance genes not traditionally associated with CRC (3, ATM; 1, ATM/CHEK2; 2, BRCA1; 4, BRCA2; 1, CDKN2A; 2, PALB2); 10 patients had mutations in low-penetrance CRC genes (3, APC c.3920T>A, p.I1307K; 7, monoallelic MUTYH).
|
27978560 |
2017 |
Colorectal Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
SMAD4 is a polypeptide with tumor suppressor function being investigated as a prognostic biomarker in Union Internationale Contre le Cancer stages II and III in previous studies, but its role as a prognostic marker in stage IV colorectal cancer (CRC) is still undefined.
|
21609932 |
2011 |
Colorectal Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Among 734 patients with CRC, 90 (12%) had SMAD4 mutations according to hotspot testing.
|
28267766 |
2017 |
Colorectal Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Colorectal cancers (CRCs) frequently harbor somatic mutations in the pathway members TGFBR2 and SMAD4, but to what extent mutations in SMAD2 or SMAD3 contribute to tumorigenesis is unclear.
|
23139211 |
2013 |
Colorectal Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
These results indicate that whereas Smad4 point mutations are prevalent in pancreatic carcinoma, they are infrequent in early stages (I-III) of colorectal cancer.
|
12569386 |
2003 |
Colorectal Carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Compared to the 152 non-hypermutated CONs from TCGA database, SMAD4 alteration was predominant in SRC/SRCC (p = 0.045) with aberrant loss of SMAD4 expression (13/17, 76.5%) compared to the SMAD4 alterations in CON (5/15, 33.3%) (p = 0.031).
|
31400926 |
2019 |
Colorectal Carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Utilising a recently developed method of immunohistochemical staining for Smad4 protein, we focused on the specific impact of Smad4 protein expression on liver metastasis in colorectal cancer.
|
17088901 |
2006 |
Colorectal Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
However, thus far few studies have analyzed the impact of numerical abnormalities of chromosomes 17 and 18, which carry the p53 and DCC plus SHAD4/DPC4 genes involved in colorectal cancer, on the clinical and biological behaviors of the disease.
|
12500293 |
2003 |
Colorectal Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Loss of heterozygosity on chromosome 18 can case SMAD4-deficient CRC, which results in poorer patients' survival.
|
31756952 |
2019 |
Colorectal Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
RT-PCR sequencing analysis of the HL60 Smad5 remaining allele ruled out the functional inactivation of the gene analogous to that occurring in the Smad5 homologs DPC4 and Smad2 in cases of pancreatic and colorectal cancers.
|
9264367 |
1997 |
Colorectal Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
A transducer of TGF-beta signaling known as Mothers against decapentaplegic homologue 4 (Smad4) is a known tumor suppressor found on chromosome 18q21.1 and is typically inactivated by deletion or mutation in pancreatic and colorectal cancers.
|
18213629 |
2008 |
Colorectal Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Seven significantly mutated genes, including four reported (APC, TP53, KRAS and SMAD4) and three novel recurrently mutated genes (CDH10, FAT4 and DOCK2), exhibited high mutation prevalence (6-14% for novel cancer genes) and higher-than-expected number of non-silent mutations in our CRC cohort.
|
24951259 |
2015 |
Colorectal Carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
The correlation of USP3, SMAD4 and miR-224 expression was further verified in CRC specimens.
|
28655924 |
2017 |
Colorectal Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The aim of this study was to evaluate the clinicopathological characteristics and clinical significance of SMAD4 alteration detected with NGS in CRC.
|
30636020 |
2019 |
Colorectal Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Even in combination with changes in SMAD-4, the observed frequency was not sufficient to account for all 18q21 deletions in colorectal cancers.
|
9820171 |
1998 |
Colorectal Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
GTF2IRD1 downregulated the expression of the gene encoding transforming growth factor β receptor 2 (TGFβR2), a tumor-suppressor gene in Smad4-mutated CRC.
|
31758608 |
2020 |
Colorectal Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
We evaluated how the loss of Smad4 in CRC enhanced chemoresistance to 5-fluorouracil (5-FU) using two CRC cell lines in vitro and in vivo.
|
24384683 |
2014 |
Colorectal Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
The DPC4 gene may play a role as a tumor-suppressor gene in a fraction of colorectal cancers; however, while allelic loss at 18q21 is very often seen in colorectal cancers, only a minority show DPC4 mutations, suggesting that there might be another tumor-suppressor gene in this chromosome region.
|
8898652 |
1996 |
Colorectal Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Next, the prognostic value of SMAD4 mutation was validated in a separate cohort of patients with synchronous stage IV CRC who underwent systemic therapy alone.
|
29551247 |
2018 |
Colorectal Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
MiR-146b-5p was shown to increase EMT by targeting Smad4, and the miR-146b-5p-Smad4 cascade regulated EMT in CRC.
|
29722931 |
2018 |
Colorectal Carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Loss of Smad4 protein expression and 18qLOH as molecular markers indicating lymph node metastasis in colorectal cancer--a study matched for tumor depth and pathology.
|
17786972 |
2008 |